MedPath

A Dosing and Efficacy Study of Intra-nasal Sufentanil for Moderate to Severe Pain

Phase 1
Terminated
Conditions
Pain
Opiate
Interventions
Registration Number
NCT01012999
Lead Sponsor
University of Utah
Brief Summary

The purpose of this study is to determine the appropriate dose and effectiveness of intra-nasal administration of a potent narcotic, sufentanil, for the treatment of moderate to severe pain due to broken bone(s) in the arm or leg.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
16
Inclusion Criteria
  • 18 years old or older;
  • isolated traumatic injury to upper or lower extremity;
  • alert and oriented to name, date, place; patient has a numeric pain score of 5 or higher;
  • speaks English as their primary language;
  • female patients are on birth control, menopausal, or are sterile (hysterectomy, tubal ligation)
Exclusion Criteria
  • injury isolated to a finger or toe;
  • previous nasal or sinus surgery; chronic nasal problem;
  • acute nasal problem (ie epistaxis, upper respiratory infection, sinusitis);
  • pregnant; prisoner; allergy to sufentanil, fentanyl, or alfentanil; history of analgesic abuse or dependency;
  • presence of other painful injuries; systolic Blood Pressure less than 100 mm Hg;
  • patient seems or is confused or has a head injury; room air oxygenation less than 95%;
  • patient has chronic obstructive pulmonary disease, severe asthma, oxygen-dependent pulmonary disease;
  • impaired hepatic or renal function (obtained clinically or by history);
  • weight more than 230 lbs (100 kg);
  • alcohol or drug intoxication (per patient admission or clinical assessment of physician);
  • elderly (> 70 years)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Intranasal sufentanil, pain reliefsufentanilIntranasal sufentanil administered at a dose of 0.5 mcg/kg times one dose at beginning of thirty minute period
Primary Outcome Measures
NameTimeMethod
Pain Relief at Thirty Minutes30 min post dose

Measured pain relief on a visual analog scale (0-10- ten being the worst pain and zero being no pain at all).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Utah Health Sciences Center

🇺🇸

Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath